Dalteparin as periprocedure anticoagulation for patients on warfarin and at high risk of thrombosis

BACKGROUND: Patients taking warfarin and at high risk for thromboembolic complications have traditionally been hospitalized for two to three days to receive standard treatment with intravenous heparin both prior to and following procedures while their international normalized ratio (INR) is subtherapeutic. OBJECTIVE: To assess the feasibility of protocol implementation for outpatient anticoagulation with low-molecular-weight heparin to eliminate or reduce the length of hospital admission needed solely for anticoagulation. METHODS: Patients included were receiving warfarin for a prosthetic heart valve, mitral valve disease with atrial fibrillation, or recent episode of venous thromboembolism. Warfarin was discontinued four days prior to the procedure. Subcutaneous dalteparin 200 units/kg was given on the two mornings prior to the procedure and restarted 12-24 hours after the procedure until the INR was in the therapeutic range. Warfarin was reinitiated on the evening of surgery. RESULTS: Twenty-four patients underwent 26 procedures. There were two minor bleeding complications, and one patient experienced a transient ischemic attack. Patients received a median of five days of dalteparin. The INR returned to the therapeutic range on the median postoperative day 4. All patients avoided two days of hospitalization prior to the procedure (i.e., no patients needed to be admitted preoperatively for anticoagulation). A median of four days would have been required for the sole purpose of postoperative anticoagulation. CONCLUSIONS: Outpatient perioperative anticoagulation with dalteparin for high-risk patients requiring long-term oral anticoagulation appears feasible and warrants further study.

This article has been cited by other articles:

				J. D. Douketis, P. B. Berger, A. S. Dunn, A. K. Jaffer, A. C. Spyropoulos, R. C. Becker, and J. Ansell The Perioperative Management of Antithrombotic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 299S - 339S. [Abstract] [Full Text] [PDF]

				N Rivas-Gandara, I Ferreira-Gonzalez, P Tornos, A Torrents, G Permanyer-Miralda, I Nicolau, E Arellano-Rodrigo, N Vallejo, A Igual, and J Soler-Soler Enoxaparin as bridging anticoagulant treatment in cardiac surgery Heart, February 1, 2008; 94(2): 205 - 210. [Abstract] [Full Text] [PDF]

				A. C. Spyropoulos Outpatient-Based Primary and Secondary Thromboprophylaxis With Low-Molecular-Weight Heparin Clinical and Applied Thrombosis/Hemostasis, January 1, 2008; 14(1): 63 - 74. [Abstract] [PDF]

				A. Vincentelli, B. Jude, and S. Belisle Antithrombotic therapy in cardiac surgery: [Traitement antithrombotique en chirurgie cardiaque]. Can J Anesth, June 1, 2006; 53(6_suppl): S89 - S102. [Abstract] [Full Text] [PDF]

				B. E. Ickx and A. Steib Perioperative management of patients receiving vitamin K antagonists: [Prise en charge perioperatoire des patients traites aux antagonistes de la vitamine K] Can J Anesth, June 1, 2006; 53(6_suppl): S113 - S122. [Abstract] [Full Text] [PDF]

				B. J. G. Larson, M. S. Zumberg, and C. S. Kitchens A Feasibility Study of Continuing Dose-Reduced Warfarin for Invasive Procedures in Patients With High Thromboembolic Risk Chest, March 1, 2005; 127(3): 922 - 927. [Abstract] [Full Text] [PDF]

				U. K. H. Wiegand, D. LeJeune, F. Boguschewski, H. Bonnemeier, F. Eberhardt, H. Schunkert, and F. Bode Pocket Hematoma After Pacemaker or Implantable Cardioverter Defibrillator Surgery: Influence of Patient Morbidity, Operation Strategy, and Perioperative Antiplatelet/Anticoagulation Therapy Chest, October 1, 2004; 126(4): 1177 - 1186. [Abstract] [Full Text] [PDF]

				M.J. Kovacs, C. Kearon, M. Rodger, D.R. Anderson, A.G.G. Turpie, S.M. Bates, L. Desjardins, J. Douketis, S.R. Kahn, S. Solymoss, et al. Single-Arm Study of Bridging Therapy With Low-Molecular-Weight Heparin for Patients at Risk of Arterial Embolism Who Require Temporary Interruption of Warfarin Circulation, September 21, 2004; 110(12): 1658 - 1663. [Abstract] [Full Text] [PDF]

				J. Ansell, J. Hirsh, L. Poller, H. Bussey, A. Jacobson, and E. Hylek The Pharmacology and Management of the Vitamin K Antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 204S - 233S. [Abstract] [Full Text] [PDF]

				J. D. Douketis, J. A. Johnson, and A. G. Turpie Low-Molecular-Weight Heparin as Bridging Anticoagulation During Interruption of Warfarin: Assessment of a Standardized Periprocedural Anticoagulation Regimen Arch Intern Med, June 28, 2004; 164(12): 1319 - 1326. [Abstract] [Full Text] [PDF]

				L. M Heuts, B. M M. Arvik, and D. E Cender LMWH for Perioperative Anticoagulation in Patients on Chronic Warfarin Therapy Ann. Pharmacother., June 1, 2004; 38(6): 1065 - 1069. [Abstract] [Full Text] [PDF]

				A. C. Spyropoulos, F. J. Frost, J. S. Hurley, and M. Roberts Costs and Clinical Outcomes Associated With Low-Molecular-Weight Heparin vs Unfractionated Heparin for Perioperative Bridging in Patients Receiving Long-term Oral Anticoagulant Therapy Chest, May 1, 2004; 125(5): 1642 - 1650. [Abstract] [Full Text] [PDF]

				J. E. Ansell The Perioperative Management of Warfarin Therapy Arch Intern Med, April 28, 2003; 163(8): 881 - 883. [Full Text] [PDF]

				A. S. Dunn and A. G. G. Turpie Perioperative Management of Patients Receiving Oral Anticoagulants: A Systematic Review Arch Intern Med, April 28, 2003; 163(8): 901 - 908. [Abstract] [Full Text] [PDF]

				A. I. Schafer, M. N. Levine, B. A. Konkle, and C. Kearon Thrombotic Disorders: Diagnosis and Treatment Hematology, January 1, 2003; 2003(1): 520 - 539. [Abstract] [Full Text] [PDF]